MA46750A - Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents - Google Patents

Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents

Info

Publication number
MA46750A
MA46750A MA046750A MA46750A MA46750A MA 46750 A MA46750 A MA 46750A MA 046750 A MA046750 A MA 046750A MA 46750 A MA46750 A MA 46750A MA 46750 A MA46750 A MA 46750A
Authority
MA
Morocco
Prior art keywords
ralinepag
agents
combinations
methods
treating pah
Prior art date
Application number
MA046750A
Other languages
English (en)
Inventor
John W Adams
Dominic P Behan
Lucie H Clapp
Original Assignee
Arena Pharm Inc
Lucie H Clapp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc, Lucie H Clapp filed Critical Arena Pharm Inc
Publication of MA46750A publication Critical patent/MA46750A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA046750A 2016-11-10 2017-11-10 Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents MA46750A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662420515P 2016-11-10 2016-11-10
US201762530533P 2017-07-10 2017-07-10

Publications (1)

Publication Number Publication Date
MA46750A true MA46750A (fr) 2019-09-18

Family

ID=60451197

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046750A MA46750A (fr) 2016-11-10 2017-11-10 Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents

Country Status (10)

Country Link
US (1) US20190321328A1 (fr)
EP (1) EP3538154A1 (fr)
JP (2) JP2019533713A (fr)
KR (3) KR20200015439A (fr)
CN (1) CN110691612A (fr)
AU (2) AU2017357759A1 (fr)
CA (1) CA3043283A1 (fr)
IL (1) IL266518A (fr)
MA (1) MA46750A (fr)
WO (1) WO2018089804A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018227842B2 (en) 2017-03-01 2024-05-02 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
US20210212979A1 (en) * 2018-05-16 2021-07-15 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
CN108721296B (zh) * 2018-07-03 2019-04-05 中国人民解放军总医院 一种化合物在治疗或预防高原病中的用途
CN112638865B (zh) * 2018-09-06 2022-07-26 广东东阳光药业有限公司 药物共晶体及其制备方法
SI3897646T1 (sl) 2018-12-21 2024-08-30 ACTELION PHARMACEUTICALS lTD, Makitentan za zdravljenje pljučne arterijske hipertenzije
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
KR20240024285A (ko) 2008-03-18 2024-02-23 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
EP2480526A1 (fr) * 2009-09-23 2012-08-01 Arena Pharmaceuticals, Inc. Formes cristallines et procédés pour la préparation d'agonistes du récepteur pgi2
WO2013040068A2 (fr) * 2011-09-12 2013-03-21 Irix Pharmaceuticals, Inc. Procédé de préparation de prostacyclines synthétiques
AU2013351934B2 (en) * 2012-11-30 2018-03-29 Insmed Incorporated Prostacylin compositions and methods for using the same
CN114452279A (zh) * 2014-10-23 2022-05-10 艾尼纳制药公司 治疗与pgi2受体相关的病症的方法
US20180325875A1 (en) * 2015-01-13 2018-11-15 Vivus, Inc. Combination therapy for pulmonary hypertension

Also Published As

Publication number Publication date
KR20240068077A (ko) 2024-05-17
KR20200015439A (ko) 2020-02-12
WO2018089804A1 (fr) 2018-05-17
CA3043283A1 (fr) 2018-05-17
CN110691612A (zh) 2020-01-14
JP2019533713A (ja) 2019-11-21
AU2017357759A1 (en) 2019-06-06
KR20230021186A (ko) 2023-02-13
IL266518A (en) 2019-07-31
WO2018089804A9 (fr) 2018-06-21
EP3538154A1 (fr) 2019-09-18
AU2023263497A1 (en) 2023-11-30
US20190321328A1 (en) 2019-10-24
JP2023029865A (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
MA46750A (fr) Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
MA45192A (fr) Traitement d'association
MA51770A (fr) Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA42450A (fr) Méthodes de traitement de la stéatose hépatique non alcoolique et/ou de la lipodystrophie
MA46102A (fr) Composés de tétracycline et méthodes de traitement
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA50264A (fr) Méthodes de traitement des infections de type hépatite b
DK3364997T3 (da) Aspartoacylase genterapi til behandling af canavans sygdom
MA43817A (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
MA46365A (fr) Méthodes de traitement de troubles mitochondriaux et métaboliques
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA44526A (fr) Oxystérols et leurs méthodes d'utilisation
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
MA41120A (fr) Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation